|
|
 |
|
|
Australian institute for bioengineering and nanotechnology andbiosceptre collaborate on cancer anti by ferujkll sdff
|
|
|
Australian institute for bioengineering and nanotechnology andbiosceptre collaborate on cancer anti by FERUJKLL SDFF
|
|
| Article Posted: 11/08/2013 |
| Article Views: 156 |
| Articles Written: 2023 - MORE ARTICLES FROM THIS AUTHOR |
| Word Count: 741 |
| Article Votes: 0 |
|
Australian institute for bioengineering and nanotechnology andbiosceptre collaborate on cancer anti |
|
|
|
|
|
Business,Business News,Business Opportunities
|
|
Posted: May 15th, 2012 Australian Institute for Bioengineering and Nanotechnology andBiosceptre collaborate on cancer antibody research ( Nanowerk News ) UniQuest, The University of Queensland's (UQ) maincommercialisation company, has facilitated a strategic researchcollaboration and antibody production agreement between AustralianInstitute for Bioengineering and Nanotechnology (AIBN) researchersand Biosceptre International Limited to develop a bioprocess forproducing certain monoclonal antibodies for the treatment ofcancer. Under the UniQuest agreement, the AIBN's National BiologicsFacility (NBF) will characterise candidate therapeutic monoclonalantibodies that bind Biosceptre's novel proprietary cancer target,known as nf-P2X7. The research and development will includeantibody development, cell line development, bioprocess developmentand recombinant protein production in pre-commercial quantitiesahead of preclinical trials. UniQuest Managing Director, David Henderson, said the partnershipwith Biosceptre reflected the commitment by UQ and the AIBN to workclosely with private industry to discover new potential cancertherapies. "Cancer is the second leading cause of death worldwide and thedisease with the highest unmet medical need.
Biosceptre'srecognition of the AIBN's capabilities demonstrates the valueindustry places on working with Australian university researchersto optimise the outcomes from both publicly and privately fundedresearch for the benefit of the wider community," Mr Hendersonsaid. The collaboration was made possible with support from Medigen, aprivately held investment company which is linked to the Creatagroup of companies and utilises the services of Creata Ventures. No commercial terms of the agreement have been disclosed. Biosceptre's CEO, Dr Cliff Holloway, said the researchcollaboration was a critical step towards preclinical and humanclinical trials involving its monoclonal antibody targeting thenon-functional form of P2x7, a major cellular receptor responsiblefor apoptosis (the process of normal cell death). "Our long-term goal is to develop a therapeutic monoclonal antibodycapable of specifically detecting non-functional P2X7 and inducingcancer cell death without affecting normal healthy cells," DrHolloway said.
"Having evaluated a number of national and international providersof such antibody services, we have been impressed with the advancedequipment and quality of the infrastructure at the AIBN NationalBiologics Facility. The technical expertise of Dr David Chin, NBFOperations Manager, and his team in our pre-deal evaluation hasalready delivered value for Biosceptre." Biosceptre recently appointed eminent monoclonal antibody pioneerSir Greg Winter as Chairman of its Scientific Advisory Board. TheBritish biochemist, who developed the world's first fully humantherapeutic antibody, included a tour of AIBN's National BiologicsFacility and a discussion on the AIBN iosceptre collaborationduring his visit to Australia earlier this year. About UniQuest Pty Limited Established by The University of Queensland in 1984, UniQuest iswidely recognised as one of Australia's largest and most successfuluniversity commercialisation groups, benchmarking in the top tierof technology transfer worldwide. From an intellectual propertyportfolio of 1,500+ patents it has created over 70 companies, andsince 2000 UniQuest and its start-ups have raised more than $450million to take university technologies to market.
Annual sales ofproducts using UQ technology and licensed by UniQuest are runningat $3 billion. UniQuest now commercialises innovations developed atThe University of Queensland and its commercialisation partnerinstitutions: the University of Wollongong, University ofTechnology Sydney, James Cook University, University of Tasmania,Mater Medical Research Institute, and Queensland Health. UniQuestalso provides access to an expansive and exclusive network ofindependent academics to tailor a consulting or project R&Dsolution to meet the diverse needs of industry and government,facilitating some 500 consulting, expert opinion, testing, andcontract research services each year. UniQuest is also a leadingAustralasian provider of international development assistancerecognised for excellence in technical leadership, management andresearch. Working with agencies such as AusAID, NZAID, the AsianDevelopment Bank and the World Bank, UniQuest has developed andimplemented more than 400 projects in 60+ countries throughout thePacific, South-East Asia, the Indian sub-continent and Africa..au About AIBN The University of Queensland's Australian Institute forBioengineering and Nanotechnology (AIBN) is an integratedmulti-disciplinary research institute bringing together the skillsof world-class researchers in the areas of bioengineering andnanotechnology.
It is home to 19 research groups working at theinterface of the biological, chemical and physical science toalleviate current problems in human health and environmentalissues. AIBN research focuses on developing new products, processesand devices for improving human health and quality of life. In thisway the institute goes beyond basic research to promote and developthe growth of innovative industries, which will benefit theQueensland and Australian economies. The AIBN proudly acknowledgesthe financial support of Atlantic Philanthropies, the QueenslandState Government and the University of Queensland toward theconstruction of the AUD$75 million AIBN research facility. I am an expert from Power Supplies, usually analyzes all kind of industries situation, such as tree pruning tools , retrospect backup software.
Related Articles -
tree pruning tools, retrospect backup software,
|
Rate This Article  |
|
|
|
|
|
Do you Agree or Disagree? Have a Comment? POST IT!
| Reader Opinions |
|
|
|
|
|
|
|
|
|
| Author Login |
|
|
 |
Advertiser Login
ADVERTISE HERE NOW!
Limited Time $60 Offer!
90 Days-1.5 Million Views
|
|
STEPHEN BYE
Stephen Bye is a fiction writer. His most recent novels are a 5-book “The Developer” series which be...more
|
|
|
|
|
GENE MYERS
Author of four books and two screenplays; frequent magazine contributor. I have four other books "in...more
|
|
|
|
|
TIM FAY
After 60-plus years of living, I am just trying to pass down some of the information that I have lea...more
|
|
|
|
|
ADRIAN JOELE
I have been involved in nutrition and weight management for over 12 years and I like to share my kn...more
|
|
|
|
|
LAURA JEEVES
At LeadGenerators, we specialise in content-led Online Marketing Strategies for our clients in the t...more
|
|
|
|
|
MICHAEL BRESCIANI
Rev Bresciani is the author of two Christian books. One book is an important and concisely written b...more
|
|
|
|
|
LEVAL AINAH
I am an internet marketer and also an educator. My goal is to help others who are looking to improve...more
|
|
|
|
|
PAUL PHILIPS
For more articles, blog messages & videos and a free e-book download go to www.NewParadigm.ws your p...more
|
|
|
|
|
ALEX BELSEY
I am the editor of QUAY Magazine, a B2B publication based in the South West of the UK. I am also the...more
|
|
|
|
